Barbara J. Rutledge, Ph.D.
Tazarotene, dermoscopy effective for sBCC
Washington, D.C. — Topical application of tazarotene 0.1 percent gel for up to 20 weeks, with treatment efficacy monitored using dermoscopy, can be an effective treatment regimen for patients with superficial basal cell carcinoma (sBCC), according to Claudia Cotellessa, M.D., a dermatologist at the University of L'Aquila, Italy. Surgical excision and Mohs micrographic surgery are the standard treatments for basal cell carcinoma. However, a surgical approach may not be the best choice for all patients with sBCC, says Dr. Cotellessa.
Combo of generic/specific questionnaires yeilds thorough QoL assessment of psoriatic patients
Rome - For the most complete assessment of the quality of life of patients with psoriasis, dermatologists should combine a generic questionnaire with a dermatology-specific questionnaire, according to Francesca Sampogna, B.D., M.P.H., a post-doctoral fellow at the Istituto Dermopatico dell'Immacolata (IDI-IRCCS) here.
Pimecrolimus cream shows better tolerability
Washington - Pimecrolimus cream 1 percent showed better local tolerability than tacrolimus ointment 0.03 percent in pediatric patients with moderate atopic dermatitis, and the patients or their primary caregivers rated most of the formulation attributes of the pimecrolimus cream as being significantly better than those of the tacrolimus ointment, according to a recent Phase IV study presented at the American Academy of Dermatology annual meeting.
Combo useful for pediatric dermatitis
Pimecrolimus cream, corticosteroids work together safely for severe flares
Avoiding false negatives in dermoscopic diagnosis of melanoma
Total body photography, digital dermoscopy work as 'two-step follow-up' for identification
Metronidazole conquers EAC
Washington - Systemic metronidazole can be an effective treatment for erythema annulare centrifugum (EAC), according to Lucio Andreassi, M.D., professor and chairman of the Department of Dermatology at the University of Siena, Italy. At the annual AAD meeting, Dr. Andreassi presented a case report of a patient with a two-year history of EAC who was successfully treated with a six-week course of oral metronidazole, followed by a four-week course of topical metronidazole 1 percent gel.
Pyruvic acid offers gentle acne therapy
Washington - Facial peeling with pyruvic acid is an effective and well-tolerated treatment for patients with mild-to-moderate papulopustular acne, according to Alessia Pacifico, M.D., a dermatologist at the University of L'Aquila. Dr. Pacifico and colleagues evaluated the efficacy and tolerability of topical application of a solution of 40 to 50 percent pyruvic acid in a study enrolling 24 subjects with mild to moderate papulo-pustular acne.
Clinical variants dictate KS treatment
Washington, D.C. - There are several clinical variants of Kaposi's sarcoma (KS), and appropriate treatment and response to treatment differ according to the clinical variant, according to Katie Pang, M.D., a clinical research fellow working with Dr. Stephen Tyring at the Center for Clinical Studies in Houston, Texas. The four major clinical variants are classic KS, KS in iatrogenically immunosuppressed patients, AIDS-related epidemic KS, and African endemic KS. HHV-8 is the etiological agent of all of the clinical types of KS.
Diagnostic challenge
Washington - The standard multi-drug therapy for multi-bacillary leprosy (MDT-MB) recommended by the World Health Organization proved effective in treating patients with Lucio's phenomenon, a rare necrotizing reaction sometimes seen in patients with Lucio's leprosy, according to Luna Azulay-Abulafia, assistant professor of dermatology at the Universidade do Estado do Rio de Janeiro and at the Universidade Gama Filho, Brazil. At the February American Academy of Dermatology annual meeting, Dr. Azulay-Abulafia described two cases of Lucio's phenomenon in Brazilian patients with Lucio's leprosy successfully treated with MDT-MB, with no need for systemic therapy with corticosteroids or thalidomide.
Rud's syndrome
Washington - Topical application of tazarotene 0.05 percent was effective in reducing cutaneous roughness and scaling in a patient with a rare form of ichthyosis known as Rud's syndrome, according to Maria Concetta Fargnoli, M.D., a dermatologist at the University of L'Aquila, Italy.


View Results